In this “Experts Arena”, retina specialists express their opinions, and look into the foreseen c

In this video, Patricia Udaondo, MD, PhD, shares her thoughts on Eylea HD and the prefilled syringe,

In this video, Anat Loewenstein, MD has interviewed Jasmina Kapetanovic, MD, PhD about the state of

Tuesday June 4, at 6.30 p.m. CEST, key opinion leaders will be with us for

In this one-on-one conversation with Paolo Lanzetta, MD, Tunde Peto, MD, PhD, gives tips and example

In this video, Anat Loewenstein, MD, and Srinivas Sadda, MD, share their experience in the field and

The Intravitreal Expert Group joins the whole retina community in expressing deepest condolences for

In this video, Paolo Lanzetta, MD, speaks with Sundaram Natarajan, MD, about the Aditya Jyot-study o

Myopia is on the rise globally, and has been more so since the COVID-19 pandemic.

With the new treatments for GA, it is important to re-think the management of patients looking at th

Paolo Lanzetta discusses with Baruch Kuppermann about the new treatments for geographic atrophy appr

IVEG instructional course – Euretina 2023 Take-home messages In this video, the best of our

On 8 October at the Euretina 2023 congress in Amsterdam, international TLs will discuss controversie

Paolo Lanzetta, MD, interviews Anat Loewenstein, MD, on home monitoring, a technology in which her r

Paolo Lanzetta, MD, and Jean-François Korobelnik, MD, PhD, speak about high-dose Aflibercept and th

The U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) 8mg injection for th

Paolo Lanzetta, MD interviews Andrii Korol, MD about the situation of ophthalmology in Ukraine.

Regeneron announced that the FDA issued a CRL to the approval application for aflibercept 8 mg for t

A study reviews evidence and provides recommendations for the ideal setting of intravitreal injectio

Professor Jean-François Korobelnik reviews the results at one year of the PHOTON and PULSAR studies

A study performed at the Rothschild Foundation Hospital in Paris showed that pediatric eye injuries

Diabetic Eye Screening campaigns have a key role in the prevention and treatment of diabetic related

A retrospective, population-based study showed that there is no association between RVO and mRNA COV

Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi

Biosimilars entering the scene of intravitreal injections

A new optogenetic therapy is on the horizon

Aviceda Therapeutics submitted Investigational New Drug (IND) and Fast Trac

Retina thought leaders give opinions on new treatments for nAMD

On February 17, the FDA approved SYFOVRE™ (pegcetacoplan, Apellis Pharmac

FDA has accepted for priority review the Biologics License Application (BLA

To tackle diabetes-related eye diseases through a multidisciplinary team approach.

In the CENTERA study, significant functional and anatomic improvements were

Where are we now with the spread of these therapies for AMD to prevent blindness?

What do the studies show? What do the experts think?

Home monitoring, intravitreal treatments, gene therapy, AI. The future of ophthalmology through the

Data from a retrospective real world study highlights low incidence of proactive treatment of nAMD